1,2-dipentadecanoyl-sn-glycero-3-phosphorylcholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 1,2-dipentadecanoyl-sn-glycero-3-phosphorylcholine
• 英文别名: 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine；L-α-dimyristoylphosphatidylcholine；dimyristoylphosphatidylcholine；1,2-dipentadecanoyl-sn-glycero-3-phosphocoline；L-α--lecithin；[(2R)-2,3-di(pentadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• 化学式: C₃₈H₇₆NO₈P
• 分子量: 705.997
• InChiKey: LJARBVLDSOWRJT-PSXMRANNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.4
• 重原子数：
  48
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  十五烷酰氯 、 甘磷酸胆碱 以 氯仿 为溶剂， 生成 1,2-dipentadecanoyl-sn-glycero-3-phosphorylcholine
  参考文献：
  名称：

  Koegl,F. et al., Recueil des Travaux Chimiques des Pays-Bas, 1960, vol. 79, p. 661 - 674

  摘要：

  DOI：

文献信息

• Functional associative coatings for nanoparticles
  申请人：Hainfeld James F.

  公开号：US20080089836A1

  公开（公告）日：2008-04-17

  Described herein are nanoparticles that are coated with a bilayer of molecules formed from surface binding molecules and amphiphatic molecules. The bilayer coating self assembles on the nanoparticles from readily available materials/molecules. The modular design of the bilayer coated nanoparticles provides a means for readily and efficiently optimizing the properties of the bilayer coated nanoparticle compositions. Also described herein are uses of such nanoparticles in medicine, laboratory techniques, industrial and commerical applications.

  本文描述了一种纳米颗粒，其表面涂覆有由表面结合分子和两亲分子形成的双层分子层。该双层涂层可以自组装在纳米颗粒上，使用易得的材料/分子。双层涂层纳米颗粒的模块化设计提供了一种方便和高效地优化其性质的方法。此外，本文还描述了这种纳米颗粒在医学、实验室技术、工业和商业应用中的用途。
• Modulation of release from dry powder formulations
  申请人：Basu K. Sujit

  公开号：US20050003003A1

  公开（公告）日：2005-01-06

  Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.

  含有生物活性物质的微粒被制备成具有所需的基质转变温度。通过肺系统输送微粒会导致药物从微粒中释放的调节。通过形成包含彼此相溶且具有高基质转变温度的磷脂组合的微粒，可以获得药物的持续释放和/或持续药理作用。
• Polypeptides of pseudomonas aeruginosa
  申请人：ID Biomedical Corporation

  公开号：EP1790659A2

  公开（公告）日：2007-05-30

  The present invention is related to polypeptides, more particularly SPA-1, SPA-2 and SPA-3 polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.

  本发明涉及可用于预防、诊断和/或治疗铜绿假单胞菌感染的多肽，尤其是铜绿假单胞菌的 SPA-1、SPA-2 和 SPA-3 多肽。
• AMINO ACID-, PEPTIDE- AN POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AN USES THEREOF
  申请人：Massachusetts Institute Of Technology

  公开号：EP4074694A1

  公开（公告）日：2022-10-19

  Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as "APPLs". Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R', R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.

  本文描述的化合物和组合物，在某些实施方案中，通过将各种基团（如亲油基团）与氨基酸的氨基或酰胺基团、线性或环状肽、线性或环状多肽或其结构异构体共轭，以提供本发明的化合物，本文统称为 "APPLs"。此类 APPL 被认为可用于多种应用，例如，改善核苷酸递送。示例性 APPL 包括但不限于本文所述的式 (I)、(II)、(III)、(IV)、(V) 和 (VI) 及其盐类化合物： 其中 m、n、p、R'、R1、R2、R3、R4、R5、R8、Z、W、Y 和 Z 如本文所定义。
• Composition for on-demand ultrasound-triggered drug delivery
  申请人：Kohane Daniel S.

  公开号：US10010709B2

  公开（公告）日：2018-07-03

  Injectable or implantable drug delivery systems providing on-demand ultrasound-triggered drug release and methods for controlling the release of drug in a patient are provided herein. The on-demand drug delivery systems contain a drug depot and a drug encapsulated in an encapsulating material, where the encapsulating material is different from the depot. In the preferred embodiment, the depot also contains microbubbles that encapsulate one or more gases. The microbubbles enhance the drug release when ultrasound is applied compared to the same system in the absence of microbubbles. In a preferred embodiment, the drug delivery system, contains an encapsulating material, preferably liposomes, a drug to be delivered, microbubbles, and at least two hydrogel-forming precursor components. Following injection or implantation, the patient can control the time, location and dosage released by administering ultrasound.

  本文提供了按需超声触发药物释放的可注射或可植入给药系统以及控制患者体内药物释放的方法。按需给药系统包含药物库和封装在封装材料中的药物，其中封装材料与药物库不同。在优选的实施方案中，药库还包含封装一种或多种气体的微气泡。与不含微气泡的相同系统相比，微气泡可在施加超声波时增强药物释放。在一个优选的实施方案中，给药系统包含封装材料（最好是脂质体）、待给药药物、微气泡和至少两种水凝胶形成前体成分。注射或植入后，患者可通过使用超声波来控制释放的时间、位置和剂量。